Skip to main content
. 2017 Oct 27;8(60):102046–102066. doi: 10.18632/oncotarget.22143

Figure 4. GA concentrations of GA-S, GA-LP, Gal-GA-LP, Gal+GA-S, Gal+GA-LP, and Gal+Gal-GA-LP in HepG2 cells.

Figure 4

Note: Data shown represent the mean ± S.D., **P<0.05.

Abbreviations: GA-S, glycyrrhetinic acid solvent; GA-LP, glycyrrhetinic acid liposomes; Gal-GA-LP, glycyrrhetinic acid liposomes modified with liver-targeting ligand of galactosylated derivative; Gal+GA-S, galactosylated derivative was added for 4h previously, then glycyrrhetinic acid solvent was added for further 6 h; Gal+GA-LP, galactosylated derivative was added for 4 h previously, then glycyrrhetinic acid liposomes were added for further 6 h; Gal+Gal-GA-LP, galactosylated derivative was added for 4 h previously, then glycyrrhetinic acid liposomes mediated with galactosylated derivative were added for further 6 h.